FARMACIA HOSPITALARIA最新文献

{"title":"La farmacia hospitalaria rumbo al 2030","authors":"Edurne Fernández de Gamarra-Martínez ,&nbsp;Begoña Tortajada-Goitia ,&nbsp;Juan José Corte-García ,&nbsp;Isabel Martín-Herranz ,&nbsp;Mario García-Gil ,&nbsp;Javier Sáez de la Fuente ,&nbsp;Jordi Nicolás-Picó","doi":"10.1016/j.farma.2024.05.004","DOIUrl":"10.1016/j.farma.2024.05.004","url":null,"abstract":"<div><p>Hospital pharmacy is today a profession marked by therapeutic advances, with a proactive attitude, focused on people and their health. The evolution of processes is constant, with the full presence of digitalization, robotization and even artificial intelligence, in an environment that also requires the efficient and sustainable use of these tools. In this context, it is necessary to have a roadmap that guides the advancement of the profession and hospital pharmacy services.</p><p>Continuing with the philosophy of the 2020 initiative which, with the slogan “Towards the future, safely”, defined the strategic lines to advance in the improvement of hospital pharmacy practice, the Spanish Society of Hospital Pharmacy wanted to raise the challenges the profession is currently facing and with a view to 2030.</p><p>With this strategic planning objective, twenty challenges have been identified and developed, which cover the different areas of action and involvement of hospital pharmacy and which cover clinical activities, transversal aspects, training and research, as well as areas related to people and to the organizations or health systems. For each of them, the objectives, standards, tools and resources have been defined. It is also planned to provide tools that facilitate monitoring of implementation and the impact on the profession, patients and the environment.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000849/pdfft?md5=f5cd9ea05bc43b78a69679f9103d4623&pid=1-s2.0-S1130634324000849-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cuestionarios validados de adherencia a la medicación y factores asociados en pacientes crónicos: revisión sistemática","authors":"Aldana Intilangelo,&nbsp;Sofía Majic,&nbsp;Valeria Palchik,&nbsp;María Luz Traverso","doi":"10.1016/j.farma.2024.01.001","DOIUrl":"10.1016/j.farma.2024.01.001","url":null,"abstract":"<div><h3>Objective</h3><p>To identify validated questionnaires to assess medication adherence, and its associated factors, in adult patients with chronic pathologies.</p></div><div><h3>Method</h3><p>A systematic review of scientific publications that describe validated medication adherence questionnaires in PubMed and Scopus was carried out during May 2022. The search strategy combined the MeSH Heading “Medication adherence” with the keywords: “Questionnaire” and “Validation”; adding “Spanish” to rescue questionnaires in our language. Systematic reviews, meta-analyses or scientific articles with full text available in Spanish or English were selected; published from January 2000 to April 2022; that present the application and validation of a medication adherence questionnaire in adults with chronic pathologies; and publications of the initial validation of a questionnaire, recovered through bibliographic citations of the previously identified publications, even if they are prior to the year 2000.</p><p>The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed to represent the search process, inclusion and exclusion of the retrieved publications.</p></div><div><h3>Results</h3><p>Ninety-seven records in PubMed and 3 adding “Spanish” were retrieved; in Scopus, 334 records were retrieved and 13 with “Spanish”. One hundred-eighteen records were retrieved through bibliographic citations identification.</p><p>From the analysis of the previous publications, 14 validated questionnaires were identified that assess medication adherence and are applied in English and/or Spanish in adult patients with chronic pathologies. For each questionnaire, the following characteristics were described: name, authors, year of publication, dimensions (barriers and facilitators factors), number and wording of the items, response scale, form of administration, language and pathologies of the initial validation. Of the subsequent validations, only those carried out in English and/or Spanish were presented. So far, 6 questionnaires were validated in Spanish and only for certain chronic pathologies.</p></div><div><h3>Conclusions</h3><p>14 validated questionnaires were identified, 6 of them were validated in Spanish. They are designed to evaluate medication adherence in a comprehensive manner, being useful to be applied in hospital and community pharmaceutical services. This review provides health professionals with tools to develop and validate their own questionnaire, adapting the wording to the local language and context of the health system.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000023/pdfft?md5=50931a713e8bce2ac40c2ce24709255c&pid=1-s2.0-S1130634324000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139713232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of two lipid emulsions in preventing retinopathy of prematurity in preterm infants requiring parenteral nutrition","authors":"Mª José Cabañas Poy ,&nbsp;José Bruno Montoro Ronsano ,&nbsp;Félix Castillo Salinas ,&nbsp;Nieves Martín-Begué ,&nbsp;Susana Clemente Bautista ,&nbsp;Mª Queralt Gorgas Torner","doi":"10.1016/j.farma.2023.10.005","DOIUrl":"10.1016/j.farma.2023.10.005","url":null,"abstract":"<div><h3>Objectives</h3><p>The main aim was to compare the effects of 2 parenteral lipid emulsions on retinopathy of prematurity (ROP) incidence, severity, and need for treatment. Secondary aim was to compare the effect on weight gain in the first 6 weeks of life.</p></div><div><h3>Methods</h3><p>Single-center, observational, retrospective study analyzing preterm infants with a gestational age (GA) &lt;<!--> <!-->31 weeks and a birth weight &lt;<!--> <!-->1251 g born between April 2015 and December 2018. The infants' medical records were reviewed to collect clinical data. Parenteral nutrition (PN) details were obtained from the hospital pharmacy database.</p></div><div><h3>Results</h3><p>In total, 180 patients were included: 90 received ClinOleic® and 90 received SMOFlipid®. No significant differences were observed for the incidence of ROP (40% in ClinOleic® group and 41% in SMOFlipid® group, <em>p</em> <!-->=<!--> <!-->.88) or ROP requiring treatment (4% and 10%, respectively, <em>p</em> <!-->=<!--> <!-->.152). Weekly weight gain was similar in the 2 groups.</p></div><div><h3>Conclusions</h3><p>This study showed no difference between the 2 groups regarding ROP, ROP requiring treatment, or weekly weight gain in the first 6 weeks of life.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634323009017/pdfft?md5=adaef8288dc797f7634a54fd37182a9b&pid=1-s2.0-S1130634323009017-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio de estabilidad fisicoquímica y microbiológica de dos nuevos colirios de metilprednisolona sin conservantes","authors":"Vicente Merino-Bohórquez ,&nbsp;Silvia Berisa-Prado ,&nbsp;Mercedes Delgado-Valverde ,&nbsp;María José Tirado-Pérez ,&nbsp;Marta García-Palomo ,&nbsp;José María Alonso-Herreros ,&nbsp;Carme Cañete-Ramírez ,&nbsp;María del Dávila-Pousa ,&nbsp;& Grupo de Trabajo de Farmacotecnia de la Sociedad Española de Farmacia Hospitalaria","doi":"10.1016/j.farma.2024.01.007","DOIUrl":"10.1016/j.farma.2024.01.007","url":null,"abstract":"<div><h3>Objective</h3><p>To study the physicochemical and microbiological stability over 90 days of two preservative-free methylprednisolone sodium succinate (MTPSS) 1 mg/ml and 10 mg/ml eye drops for use in ocular pathologies such as Sjögren’s syndrome and dry eye syndrome.</p></div><div><h3>Method</h3><p>The two eye drops were prepared from injectable MTPSS (Solu-moderin® and Urbason®), water for injection and normal saline solution. In accordance with ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, they were then stored in triplicate under refrigerated conditions (5 ±3 °C), at room temperature (25 ± 2 °C), and at 40 °C (±<!--> <!-->2 °C). In accordance with the USP (United States Pharmacopeia), physicochemical controls of the active ingredient content were carried out by HPLC-UV (High Performance Liquid Chromatography with Ultraviolet detection), together with controls of pH, osmolality, and visual examination. Microbiological sterility was also tested under refrigerated conditions up to 30 days in open containers and up to 90 days in closed ones.</p></div><div><h3>Results</h3><p>The eye drops stored at 5 °C were the most stable; in the 1 mg/ml eye drops, degradation of the drug fell below 90% from day 21, and in the 10 mg/ml eye drops, from day 42. pH change did not vary by ≥<!--> <!-->1 unit in formulations stored at 5 °C, unlike the other formulations. Changes in osmolality did not exceed 5% on day 90 in any storage conditions. Samples of non refrigerate eye drops at 10 mg/ml, presented a white precipitate from day 14 and 28 respectively. Non-refrigerated 1 mg/ml eye drops presented suspended particles on day 90. There were no color changes. Microbiological analysis showed that sterility was maintained for over 90 days in the closed containers, although microbial contamination was detected from day 21 in the open containers.</p></div><div><h3>Conclusions</h3><p>1 mg/ml MTPSS eye drops show physicochemical and microbiological stability for 21 days under refrigeration, compared to 42 days for 10 mg/ml eye drops stored under the same conditions. However, since they do not include preservatives in their composition, they should not be used for more than 7 days after opening.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000151/pdfft?md5=266cc9bcd9fbccf0b4d557d71c644142&pid=1-s2.0-S1130634324000151-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Pharmaceuticals in the environment: A hospital pharmacy perspective","authors":"Maitane Alzola-Andrés ,&nbsp;Saioa Domingo-Echaburu ,&nbsp;Maite Nogales-Garcia ,&nbsp;Itziar Palacios-Zabalza ,&nbsp;Ainhoa Urrutia-Losada ,&nbsp;Lorea Arteche-Elguizabal ,&nbsp;Amaia Lopez de Torre Querejazu ,&nbsp;Ainhoa Quintana Basterra ,&nbsp;Gorka Orive ,&nbsp;Unax Lertxundi","doi":"10.1016/j.farma.2024.04.010","DOIUrl":"10.1016/j.farma.2024.04.010","url":null,"abstract":"<div><p>Drugs do not disappear once they have been excreted. In fact, 992 active principles have already been measured in the different environmental matrices. A recent study led by scientists from the University of York has studied the presence of drugs in the rivers of more than 100 different countries, showing that environmental contamination by pharmaceuticals is a global issue and that, concentrations found are frequently harmful to the environment.</p><p>In this work, we have tried to briefly expose the problem of environmental contamination with medicines, but above all, we have tried to address the possible solutions, with a perspective from the field of hospital pharmacy. This is a very complex matter (a wicked problem), since it involves multiple stakeholders with different visions and interests regarding medicines. In order to find solutions, we will probably need to act at all steps of the drug's life cycle. Until now, health professionals have been part of the problem. It is time for us to be part of the solution.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000618/pdfft?md5=1c7acf552c7a584c47eb3e2c40a61680&pid=1-s2.0-S1130634324000618-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atención farmacéutica en enfermedades respiratorias: situación y oportunidades de la farmacia hospitalaria en España","authors":"Noé Garin ,&nbsp;Borja Zarate-Tamames ,&nbsp;Sonia Jornet ,&nbsp;Eva María García ,&nbsp;María del Mar López-Gil ,&nbsp;Gregorio Romero ,&nbsp;Jorge Del Estal ,&nbsp;Grupo de trabajo AFANES","doi":"10.1016/j.farma.2024.02.006","DOIUrl":"10.1016/j.farma.2024.02.006","url":null,"abstract":"<div><h3>Objective</h3><p>Respiratory diseases present a challenge for the healthcare system due to their prevalence and clinical impact. The aim of this study was to explore the current situation of hospital pharmacy in the field of respiratory diseases.</p></div><div><h3>Method</h3><p>Observational, cross-sectional study, with a national scope, divided into 2 parts. In an initial phase, the activity and level of pharmaceutical care in respiratory diseases was evaluated through an online questionnaire using REDCap. The survey was addressed to department chiefs and consisted of 17 items, divided into 2 modules: general data and general activity. The second phase was open to hospital pharmacists, with the aim of exploring their opinion on care, training, and improvement needs. The number of items in this phase was 19, divided into 5 modules: general data, pharmaceutical care, competencies, training and degree of satisfaction.</p></div><div><h3>Results</h3><p>In the first phase, 23 hospitals were included. Most of them (<em>n</em> <!-->=<!--> <!-->20) had a pharmacist in charge of respiratory diseases. However, a large proportion of them dedicated less than 40% of their working day to this activity. The pharmacist's activity occurred at the level of external patients (<em>n</em> <!-->=<!--> <!-->20), hospitalized patients (<em>n</em> <!-->=<!--> <!-->16), and secondarily in management (<em>n</em> <!-->=<!--> <!-->8). Integration is greater in pathologies such as asthma, IPF, pulmonary hypertension, and bronchiectasis. Participation in committees was present in 15 hospitals, with variability in pathologies and degree of involvement. In the second phase, 164 pharmacists participated, who considered pharmaceutical care in cystic fibrosis, asthma and lung transplant as a priority. Fifty-one percent considered integration to be adequate and 91% considered it necessary to implement prioritization criteria. Professional competencies ranged from 6.5-6.9 out of 10 points. Only 45% of participants had received specific training in the last four years, indicating greater priority for asthma, pulmonary hypertension and IPF.</p></div><div><h3>Conclusions</h3><p>Most centers have pharmacists specialized in respiratory diseases. However, there is room for improvement in terms of sub specialization, participation in multidisciplinary committees, implementation of prioritization criteria, diversification in pathologies treated, as well as greater specific training in this area.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000266/pdfft?md5=428af5aa38412001149d4e3c63e85b4b&pid=1-s2.0-S1130634324000266-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio retrospectivo de la terapia de infusión de antibióticos domiciliaria en bombas de infusión elastoméricas","authors":"Sara Ferro Rodríguez ,&nbsp;Yelco Chantres Legaspi ,&nbsp;Eva María Romay Lema ,&nbsp;Blanca Ayuso García ,&nbsp;Paloma Castellano Copa ,&nbsp;Pedro Peinó Camba ,&nbsp;Andrea Barcia Losada ,&nbsp;Cristina Rodríguez Díaz","doi":"10.1016/j.farma.2023.12.003","DOIUrl":"10.1016/j.farma.2023.12.003","url":null,"abstract":"<div><h3>Objectives</h3><p>To describe the experience of home antibiotic infusion therapy using elastomeric infusion pumps, administered to patients admitted to the Home Hospitalization Unit of a tertiary hospital for three years and to analyse clinical evolution and mortality.</p></div><div><h3>Method</h3><p>Retrospective observational study. The medical history of the patients included in the study was reviewed. Information was obtained on personal history, antimicrobial therapy received and clinical evolution. Statistical analysis was performed using SPSS® 19 software.</p></div><div><h3>Results</h3><p>Eighty-one patients were included, 61.7% men, with a mean age of 73.5 ± 17.5 years. The most frequent comorbidities were diabetes mellitus (30.9%) and chronic kidney disease (28.4%). Patients received a mean of 11.9 ± 8.5 days of antibiotic treatment in an elastomeric infusion pump. The main focus of infection was respiratory (27.2%), followed by bacteremia (16%) and skin and soft tissue infections (12.3%). Of the infections, 65.4% were monomicrobial, with <em>Pseudomonas aeruginosa</em> being the main microorganism involved (39.6%). The most commonly used antimicrobial was piperacillin/tazobactam (33.3%). The clinical course was good in 85.2% of the patients, but the mortality rate in the 30 days following the end of treatment was 24.7%. In the univariate analysis, a history of neoplasia in the last 5 years (p = 0.01) and having received fewer days of antibiotic therapy prior to the start of outpatient antimicrobial therapy in infusion pump (p = 0.04) were associated with worse clinical outcome.</p><p>Age over 80 years was associated with better outcome (p = 0.03). The diagnosis of heart failure was associated with higher mortality (p = 0.026) and patients from surgical services, with lower mortality (p = 0.047). In the multivariate analysis, the presence of neoplasia was associated with unfavorable evolution (p = 0.012) and heart failure with higher mortality (p = 0.027).</p></div><div><h3>Conclusions</h3><p>Outpatient antimicrobial therapy in elastomeric infusion pumps is an alternative in patients requiring prolonged intravenous treatment, and age is not a conditioning factor for inclusion in these programs. However, the presence of certain comorbidities can negatively affect the clinical course and mortality of patients.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000011/pdfft?md5=157eb518bc8961025fe02a319d30253b&pid=1-s2.0-S1130634324000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139713231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistencia de los tratamientos con dolutegravir/lamivudina y bictegravir/emtricitabina/tenofovir-alafenamida en personas con VIH en la práctica real","authors":"Lorena Martín-Zaragoza ,&nbsp;Javier Sánchez-Rubio-Ferrández ,&nbsp;Alberto Onteniente-González ,&nbsp;Marcos Gómez-Bermejo ,&nbsp;Sergio Julio Rodríguez-Álvarez ,&nbsp;Alfonso Monereo-Alonso ,&nbsp;Teresa Molina-García","doi":"10.1016/j.farma.2024.02.002","DOIUrl":"10.1016/j.farma.2024.02.002","url":null,"abstract":"<div><h3>Objetives</h3><p>The main objective was to compare the persistence between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF) and to analyze reasons for discontinuation.</p></div><div><h3>Methods</h3><p>We conducted a retrospective, non-interventional, descriptive and longitudinal study. All human immunodeficiency virus (HIV) patients over 18 years treated with DTG/3TC or BIC/FTC/TAF in our center were included.</p><p>Persistence after first year was compared using the χ² test. Kaplan-Meier survival analysis was performed.</p></div><div><h3>Results</h3><p>Three hundred fifty-eight patients were included. 99.5% versus 90.99% of patients were persistent after the first year for DTG/3TC and BIC/FTC/TAF respectively (<em>p =</em> 0.001).</p><p>Persistence with DGT/3TC was 1,237 days (IC95% 1,216-1,258) and persistence with BIC/FTC/TAF was 986 days ([IC95% 950-1,021]; <em>p</em> &lt; 0.001). The difference was remained after adjusting for covariates with the cox regression model (HR<!--> <!-->= 8.2 [IC95% 1.03-64.9], <em>p =</em> 0.047).</p><p>The main reasons for discontinuation for BIC/FTC/TAF were toxicity/tolerability.</p></div><div><h3>Conclusion</h3><p>In our study patients had a high persistence. Patients on DTG/3TC treatment were more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF was tolerability/toxicity.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000229/pdfft?md5=566f5f40674059b23252da3922fa0b73&pid=1-s2.0-S1130634324000229-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Hospital pharmacy towards 2030","authors":"Edurne Fernández de Gamarra-Martínez ,&nbsp;Begoña Tortajada-Goitia ,&nbsp;Juan José Corte-García ,&nbsp;Isabel Martín-Herranz ,&nbsp;Mario García-Gil ,&nbsp;Javier Sáez de la Fuente ,&nbsp;Jordi Nicolás-Picó","doi":"10.1016/j.farma.2024.06.008","DOIUrl":"10.1016/j.farma.2024.06.008","url":null,"abstract":"<div><p>Hospital Pharmacy is today a profession marked by therapeutic advances, with a proactive attitude, focussed on people and their health. The evolution of processes is constant, with the full presence of digitalisation, robotisation, and even artificial intelligence, in an environment that also requires the efficient and sustainable use of these tools. In this context, it is necessary to have a roadmap that guides the advancement of the profession and Hospital Pharmacy Services.</p><p>Continuing with the philosophy of the 2020 initiative which, with the slogan “Towards the future, safely”, defined the strategic lines to advance in the improvement of Hospital Pharmacy practice, the Spanish Society of Hospital Pharmacy wanted to raise the challenges the profession is currently facing and with a view to 2030.</p><p>With this strategic planning objective, 20 challenges have been identified and developed, which cover the different areas of action and involvement of Hospital Pharmacy and which cover clinical activities, transversal aspects, training, and research, as well as areas related to people and to the organisations or health systems. For each of them, the objectives, standards, tools, and resources have been defined. It is also planned to provide tools that facilitate monitoring of implementation and the impact on the profession, patients, and the environment.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324001144/pdfft?md5=66c6e15627fb445ddc2e86b99c8250dc&pid=1-s2.0-S1130634324001144-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuevos roles y retos del farmacéutico de hospital","authors":"Teresa Bermejo Vicedo ,&nbsp;Maria Queralt Gorgas ,&nbsp;Luis Margusino Framinan","doi":"10.1016/j.farma.2024.07.001","DOIUrl":"10.1016/j.farma.2024.07.001","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324001168/pdfft?md5=5710db1e580877793a548a7ec812806d&pid=1-s2.0-S1130634324001168-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}